Sage Therapeutics, Inc. (NASDAQ:SAGE) is one of the best performers on the stock market today. At current price of $158.49, the shares have already added 6.72 points (4.43% higher) from its previous close of $151.77. Should you buy or avoid them? The stock sets an active trading volume day with a reported 175173 contracts so far this session. SAGE shares had a relatively better volume day versus average trading capacity of 366.05 thousand shares, but with a 50.27 million float and a -5.61% run over a week, it’s definitely worth keeping an eye on. The one year price forecast for SAGE stock indicates that the average analyst price target is $202.5 per share. This means the stock has a potential increase of 27.77% from where the SAGE share price has been trading recently which is between $146.67 and $153.68.
The shorts are climbing into Sage Therapeutics, Inc. (SAGE) stock. The latest set of short interest data was released on 15 August 2019, and the numbers show a rise in short interest in SAGE shares. While short interest still represents only 11.02% of SAGE’s float, the number of shares shorted have risen by 561194. The number of shares shorted advanced to 5538577 shares, up from 4977383 shares during the preceding fortnight. With average daily trading volumes at 367275 shares, days to cover increased to about 12.20871 days. The most recent news story about the stock that appeared in Yahoo Finance‘s news section was titled “Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)” and dated September 05, 2019.
During the recent trading session for Sage Therapeutics, Inc. (NASDAQ:SAGE), the company witnessed their stock drop by $-4.26 over a week and tumble down $-7.22 from the price 20 days ago. When compared to their established 52-week high of $193.56, the high they recorded in their recent session happens to be lower. Their established 52-week high was attained by the company on 07/12/19. The recent low of $79.88 stood for a -18.12% since 12/24/18, a data which is good for most investors who are looking to take advantage of the stock’s recent rise. A beta of 2.56 is also allocated to the stock. Since the beta is greater than one, it implies that the stock is more volatile than the market, a data that traders are keeping close attention to.
Looking at the current readings for Sage Therapeutics, Inc., the two-week RSI stands at 41.76. This figure suggests that SAGE stock, for now, is neutral, meaning that the shares are stable in terms of price movement. The stochastic readings, on the other hand, based on the current SAGE readings is similarly very revealing as it has a stochastic reading of 22.68% at this stage. This figure means that SAGE share price today is being overbought.
Technical chart claims that Sage Therapeutics, Inc. (SAGE) would settle between $154.74/share to $157.72/share level. However, if the stock price goes below the $147.73 mark, then the market for Sage Therapeutics, Inc. becomes much weaker. If that happens, the stock price might even plunge as low as $143.7 for its downside target. The stock is currently in the red zone of MACD, with the indicator reading -6.76. Traders are always alerted for the move of a stock above or below the zero line due to the fact that the reading is an indicator of the position of the short-term average relative to the long-term average. If the MACD is above the zero line, then the short-term average relative is above that of the long-term average, thus implying an upward momentum. Vice versa is the case if the MACD is below the zero line.
Analysts at Wedbush, assumed coverage of SAGE assigning Outperform rating, according to their opinion released on May 23. Jefferies, analysts launched coverage of Sage Therapeutics, Inc. (NASDAQ:SAGE) stock with a Buy recommendation, according to their flash note issued to investors on April 25. Analysts at Wolfe Research, made their first call for the equity with a Outperform recommendation, according to a research note that dated back to December 14.
SAGE equity has an average rating of 1.47, with the figure leaning towards a bullish end. 16 analysts who tracked the company were contacted by Reuters. Amongst them, 1 rated the stock as a hold while the remaining 15 were split even though not equally. Some analysts rate the stock as a buy or a strong buy while others rated it as a sell. 14 analysts rated Sage Therapeutics, Inc. (NASDAQ:SAGE) as a buy or a strong buy while 1 advised that investors should desist from purchasing the stock or sell them if they already own the company’s stock.
Moving on, SAGE stock price is currently trading at 0X forward 12-month Consensus EPS estimates, and its P/E ratio is NA while for the average stock in the same group, the multiple is 3.8. Sage Therapeutics, Inc. current P/B ratio of 6.45 means it is trading at a premium against its industry’s 2.94.